<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422773</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-COFI-014</org_study_id>
    <nct_id>NCT00422773</nct_id>
  </id_info>
  <brief_title>Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess a maximal tolerable dose and to assess the safety of a
      chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-fluorouracil
      (5-FU)/folinic acid (FA) as first-line treatment for metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation:

      The first three patients will receive chemotherapy at the dose level 1 for 6 weeks (first
      three cycles). The dose will be escalated for the next patients by one dose level if none of
      the three patients at a dose level experience a dose-limiting toxicity (DLT) during the first
      six weeks. If one of the three patients has a DLT, an additional three patients will be
      enrolled at this dose level and the dose will be escalated if no additional patients
      experience a DLT. Otherwise, the dose escalation will be stopped, and the last dose will be
      regarded as the maximum tolerated dose (MTD). An intra-individual dose escalation is not
      planned.

      Expanded cohort:

      The MTD cohort will be expanded to a total of 16 patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess a maximal tolerable dose and the safety of a chemotherapy-combination of cetuximab, irinotecan, oxaliplatin and 5-FU/folinic acid as first-line treatment for metastatic colorectal cancer</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the treatment regarding the following: feasibility, toxicity, response rate, resection rate, progression free and overall survival</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab+ FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200</description>
    <arm_group_label>Cetuximab+ FOLFOXIRI</arm_group_label>
    <other_name>Cetuximab (C225, Erbitux by Merck)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-resectable, histologically confirmed, epithelial growth factor
             receptor(EGFR)-positive or negative colorectal cancer

          -  WHO Performance status 0 or 1

          -  Signed written informed consent

          -  ≥ 18 years of age

          -  Effective contraception for both male and female subjects if the risk of conception
             exists

          -  Adequate bone marrow function: neutrophil blood cell count (NBC) ≥ 1.5 x 10^9/L,
             platelet count ≥ 100 x 10^9/L, hemoglobin ≥ 5.96 mmol/L (10 g/dL)

          -  Adequate liver and renal function: bilirubin ≤ 1.5 x upper normal level (UNL) and not
             increasing more than 25% within the last 4 weeks; ASAT and ALAT ≤ 5 x UNL; serum
             creatinine ≤ 1.5 x UNL.

        Exclusion Criteria:

          -  Previous exposure to epidermal growth factor receptor-targeting therapy

          -  Previous chemotherapy for colorectal cancer except for adjuvant treatment with
             progression of disease documented &gt; 6 months after end of adjuvant treatment or 5-FU
             in combination with radiotherapy for rectal cancer

          -  Radiotherapy or major abdominal or thoracic surgery within the last 4 weeks before
             inclusion.

          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy.

          -  Investigational agents or participation in clinical trials within 30 days before start
             of the treatment in study.

          -  Clinically relevant coronary disease or myocardial infarction within 12 months before
             study entry.

          -  Peripheral neuropathy &gt; CTC (Common Toxicity Criteria)grade I

          -  Inflammatory bowel disease

          -  Previous malignancy (except for colorectal cancer, history of basal cell carcinoma of
             skin or pre-invasive carcinoma of the cervix with adequate treatment)

          -  History of severe psychiatric illness

          -  Drug or alcohol abuse

          -  Known hypersensitivity reaction to any of the components of study treatment

          -  Pregnancy (absence to be confirmed by b-hCG (pregnancy-) test) or lactation period

          -  Brain metastasis and/or leptomeningeal disease (known or suspected)

          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Folprecht, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Dresden, Medical Department I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutsches Tumorzentrum, Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Mannheim GmbH, III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2007</study_first_submitted>
  <study_first_submitted_qc>January 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>February 26, 2009</last_update_submitted>
  <last_update_submitted_qc>February 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gunnar Folprecht</name_title>
    <organization>University Hospital Dresden, Medical Department I</organization>
  </responsible_party>
  <keyword>phase I/II</keyword>
  <keyword>cetuximab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>irinotecan</keyword>
  <keyword>5-FU</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>dose escalation</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

